

FH Pilot Study Results

AHSN NENC CVD Prevention Programme Launch

Dr Peter Carey

On behalf of the AHSN NENC FH Steering Group

Nov 4th 2020

Phase 1 - FAMCAT

- 4 Practices - population = 45,123; **180 Expected FH**
- 6 Patients with prior FH DNA diagnosis
 - 1 undergoing testing → negative
- 303 very high risk -
 - 43 (14%) invited to screening
 - 21 (49%) attended
 - 12 eligible for testing
- 3 significant results
 - 1 positive
 - 2 VUS
- 28 1st Degree + 77 2nd Degree = Expect 33 +ve cascade testing

Re-development of Pathway

- FAMCAT tool used hard drive of GP IT system and not integrated with practice medical records - impractical to use as presented a security challenge
- Large number of patients not eligible for FH testing due to underlying secondary causes (\uparrow TG) or incomplete data
- Time consuming triaging process to identify low numbers of eligible patients
- Development of search tool incorporating NICE criteria (excluding \uparrow TG) and personal history of premature CVD < 50 yr
- Feedback from patients led to changes to patient literature and pre visit telephone call to discuss rationale for appointment

Phase 2 - CDRC

- 5 Practices - population = 49,321; **197 Expected FH**
- 9 Patients with prior FH DNA diagnosis
- 126 very high risk - 71 (56 %) invited to screening
54 (76 %) attended
53 eligible for testing - 2 declined
- 24 significant results 22 positive
2 VUS
- 19 Indexes - 6 members of 1 family
- 50 1st Degree + 89 2nd Degree = Expect 47 +ve cascade testing
- All practices had positive patients with minimum of 2 patients per practice

Summary

- Developed an optimized FH pathway based on systematic Primary Care record searches
- Incorporated patient feedback to improve awareness
- Allows guided FH genetic testing and cascade testing of relatives
- Developed for use via SystmONE and EMIS
- Aim :- meet NHS Long Term Plan target of improving FH diagnosis rates to 25% over next 5 years